Consolidated Financial Results for the Nine Months Ended September 30, 2026 [IFRS] (Summary)

November 11, 2026

Company name: Nissha Co., Ltd.
Stock exchange listing: Tokyo Stock Exchange
Code number: 7915
URL: https://www.nissha.com/english
Representative: Junya Suzuki, Chairman of the Board and Group CEO
Contact: Daisuke Inoue, Director of the Board, Senior Executive Vice President, CFO
Phone: +81-75-811-8111
Scheduled date of commencing dividend payments: -
Availability of supplementary briefing material on financial results: Available
Schedule of financial results briefing session: Scheduled (for institutional investors)

(Amounts of less than one million yen are rounded down)

1. Consolidated Financial Results for the Nine Months Ended September 30, 2026 (January 1, 2026 to September 30, 2026)

(1) Consolidated Operating Results (cumulative) (% indicates changes from the previous corresponding period)

	Net sales		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Total comprehensive income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Nine months ended September 30, 2026	144,980	(0.2)	(3,679)	–	(4,730)	–	(5,529)	–	(5,773)	–	(2,989)	–
Nine months ended September 30, 2025	145,270	(2.1)	3,508	(40.6)	2,213	(58.3)	827	(81.1)	505	(88.2)	(996)	–

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Nine months ended September 30, 2026	(121.74)	–
Nine months ended September 30, 2025	10.66	–

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
	Million yen	Million yen	Million yen	%
As of September 30, 2026	243,330	112,090	110,517	45.4
As of December 31, 2025	250,120	117,872	115,316	46.1

2. Dividends

	Annual dividends				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2025	–	25.00	–	25.00	50.00
Fiscal year ending December 31, 2026	–	25.00	–		
Fiscal year ending December 31, 2026 (Forecast)				25.00	50.00

(Note) Revision of cash dividend forecast most recently announced: No

3. Consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2026 (January 1, 2026 to December 31, 2026)

(% indicates changes from the previous corresponding period)

	Net sales		Operating profit		Profit before tax		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	195,000	0.1	(3,300)	–	(12,200)	–	(14,000)	–	(294.90)

(Note) Revision of consolidated financial results forecast most recently announced: Yes

Qualitative Information on Consolidated Financial Results for the Period under Review

Effective from the first quarter ended March 31, 2026, the categories within our reportable segments were partially reclassified, and the financial results for the nine months ended September 30, 2025 were compared and analyzed in accordance with the reclassified categories.

Explanation of operating results

The Group's Mission is to use the diverse capabilities of its people and core technologies as an engine for growth to create highly competitive, feature-rich products and services that realize customer value and contribute to better lives for all.

Guided by this Mission, as our long-term vision, we aim to create economic and social value by contributing to solving global social issues in the priority markets of Medical, Mobility, and Sustainable Materials, with the integration and orchestration of the diverse talents of our people and our technologies. Under the current 8th Medium-term Business Plan, we aim to achieve stable growth and capital efficiency improvement. Accordingly, we are working to improve and stabilize profitability through strengthening the business portfolio we have built up to date.

During the nine months ended September 30, 2026, although escalating tensions in the Middle East pushed energy prices higher, the global economy continued to show a gradual recovery, supported by factors such as expansion of AI-related demand. In the United States, although prices surged and the housing market was weak, the economy expanded gradually, supported by robust AI-related investment and higher consumer spending. In Europe, the economy was on a recovery trend mainly due to increases in consumer spending and exports, despite downward pressure from factors such as inflation caused by a rise in energy prices. In China, domestic demand remained sluggish amid factors such as a prolonged downturn in the real estate market, a decline in fixed asset investment, and weak consumer spending, resulting in an economic slowdown. In Japan, although the situation in the Middle East had some impact, the economy recovered modestly, supported by an improvement in corporate earnings and a recovery in exports and production.

Under these conditions, during the nine months ended September 30, 2026, product demand stayed solid in CDMO services for medical devices in the Medical segment and in the field of decorations in the Industrial Materials segment. On the other hand, product demand for tablets declined significantly in the Devices segment. As a result, the Group's net sales decreased compared to the same period of the previous year. As for profit, mainly due to an impairment loss on goodwill associated with USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY ("USM") recognized during the second quarter ended June 30, 2026, and an increase in costs associated with the production of exterior functional components for mobility in the Industrial Materials segment, we recorded an operating loss.

As a result, regarding the financial results for the nine months ended September 30, 2026, net sales were ¥144,980 million (a decrease of 0.2% as compared to the same period of the previous year), operating loss was ¥3,679 million (operating profit of ¥3,508 million in the previous year) and loss attributable to owners of parent was ¥5,773 million (profit attributable to owners of parent of ¥505 million in the previous year).

Following is an overview by business segment.

Medical

The Medical segment is a business segment that contributes to healthy and affluent life through the contract design/development and manufacturing organization (CDMO) services for medical devices and pharmaceuticals. For medical devices, we provide CDMO services for major medical device manufacturers, especially for those in North America and Europe, with products such as surgical instruments for minimal invasive medical treatments and medical wearable sensors used for a wide range of therapeutic areas. For pharmaceuticals, primarily in Japan, we develop our

CDMO business for over-the-counter (OTC) drugs such as cold medicines and analgesic antipyretics, and also manufacture and market our own prescription pharmaceuticals and quasi-drugs.
During the nine months ended September 30, 2026, both net sales and operating profit increased year on year, driven mainly by steady demand for our CDMO services for medical devices, as well as firm demand for our CDMO services for pharmaceuticals.
As a result, segment sales for the nine months ended September 30, 2026 were ¥43,932 million (an increase of 9.5% as compared to the same period of the previous year). Segment profit (operating profit) was ¥2,996 million (an increase of 21.3% as compared to the same period of the previous year).

Industrial Materials
In the Industrial Materials segment, we mainly offer proprietary technologies that enable the creation of added value on the surfaces of various materials. IMD and IML, which facilitate simultaneous in-mold decoration, design and function adding of plastic products, are extensively used in mobility components and home appliances in global markets. Also, the metallized paper, which unites the properties of metallic luster and printing friendliness, has the largest market share in the industry as sustainable materials for beverages and foods on a global basis.
During the nine months ended September 30, 2026, in the field of decorations, demand for home appliances remained firm, while demand for exterior functional components for mobility grew, resulting in higher net sales year on year. On the other hand, operating profit decreased year on year mainly due to an increase in costs associated with production.
As a result, segment sales for the nine months ended September 30, 2026 were ¥62,987 million (an increase of 10.4% as compared to the same period of the previous year). Segment profit (operating profit) was ¥2,278 million (a decrease of 23.9% as compared to the same period of the previous year).

Devices
In the Devices segment, we produce components and module products that pursue precision and functionality. Our main products, film-based touch sensors are adopted mainly in tablets and handheld terminals (logistics related) in global markets.
During the nine months ended September 30, 2026, demand for tablets declined significantly, and net sales decreased year on year. In addition, mainly due to an impairment loss on goodwill associated with USM recognized during the second quarter ended June 30, 2026, we recorded an operating loss.
As a result, segment sales for the nine months ended September 30, 2026 were ¥33,845 million (a decrease of 22.8% as compared to the same period of the previous year). Segment loss (operating loss) was ¥5,565 million (segment profit (operating profit) of ¥1,467 million in the previous year).